{"id":119916,"date":"2026-07-01T05:38:10","date_gmt":"2026-07-01T05:38:10","guid":{"rendered":"https:\/\/www.europesays.com\/dk\/119916\/"},"modified":"2026-07-01T13:52:20","modified_gmt":"2026-07-01T13:52:20","slug":"novo-nordisk-nvo-upgraded-to-buy-at-nordea-here-is-why-2","status":"publish","type":"post","link":"https:\/\/www.europesays.com\/dk\/119916\/","title":{"rendered":"Novo Nordisk (NVO) Upgraded to Buy at Nordea. Here is Why"},"content":{"rendered":"<p>With an annual dividend yield of 3.75%, Novo Nordisk A\/S (NYSE:<a href=\"https:\/\/finance.yahoo.com\/quote\/NVO\" target=\"_blank\" rel=\"noopener nofollow\">NVO<\/a>)\u00a0is included among the 12 Best NYSE Stocks to Buy for Dividends.<\/p>\n<p>Novo Nordisk (NVO) Upgraded to Buy at Nordea. Here is Why<\/p>\n<p class=\"text text-block paragraph text-justify neo-font-paragraph-xl-reg yf-18d6y07\" style=\"text-decoration: none; font-style: normal; text-transform: none; text-align: inherit; font-variant-numeric: normal;\">Novo Nordisk A\/S (NYSE:NVO) is a leading global healthcare company, founded in 1923 and headquartered in Denmark.<\/p>\n<p class=\"text text-block paragraph text-justify neo-font-paragraph-xl-reg yf-18d6y07\" style=\"text-decoration: none; font-style: normal; text-transform: none; text-align: inherit; font-variant-numeric: normal;\">On June 19, Nordea upgraded Novo Nordisk A\/S (NYSE:NVO) from &#8216;Hold&#8217; to &#8216;Buy&#8217; and assigned the stock a price target of DKK 350, implying an upside of 10% from the current levels.<\/p>\n<p class=\"text text-block paragraph text-justify neo-font-paragraph-xl-reg yf-18d6y07\" style=\"text-decoration: none; font-style: normal; text-transform: none; text-align: inherit; font-variant-numeric: normal;\">The analyst firm expects the near-term news flow to be favorable for the pharma company. Nordea also believes that the sales of Novo&#8217;s Wegovy pill could exceed market expectations, further supporting its bullish sentiment.<\/p>\n<p class=\"text text-block paragraph text-justify neo-font-paragraph-xl-reg yf-18d6y07\" style=\"text-decoration: none; font-style: normal; text-transform: none; text-align: inherit; font-variant-numeric: normal;\">Notably, on June 11, Novo Nordisk&#8217;s Wegovy pill became the first daily GLP-1 weight-loss pill approved in the UK. This paves the way for the Danish pharma giant to launch the drug in the second market outside the US this year, after the UAE regulator, Emirates Drug Establishment, already approved it earlier this month.<\/p>\n<p class=\"text text-block paragraph text-justify neo-font-paragraph-xl-reg yf-18d6y07\" style=\"text-decoration: none; font-style: normal; text-transform: none; text-align: inherit; font-variant-numeric: normal;\">Novo has previously revealed plans to launch the product in select markets in the second half of 2026.<\/p>\n<p>&nbsp;<\/p>\n<p class=\"text text-block paragraph text-justify neo-font-paragraph-xl-reg yf-18d6y07\" style=\"text-decoration: none; font-style: normal; text-transform: none; text-align: inherit; font-variant-numeric: normal;\">Disclosure: None.<\/p>\n","protected":false},"excerpt":{"rendered":"With an annual dividend yield of 3.75%, Novo Nordisk A\/S (NYSE:NVO)\u00a0is included among the 12 Best NYSE Stocks&hellip;\n","protected":false},"author":2,"featured_media":119917,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":"","_share_on_mastodon":"0"},"categories":[271],"tags":[46617,272,59481],"class_list":["post-119916","post","type-post","status-publish","format-standard","has-post-thumbnail","category-novo-nordisk","tag-nordea","tag-novo-nordisk","tag-pharma-company"],"share_on_mastodon":{"url":"https:\/\/pubeurope.com\/@dk\/116843112513213612","error":""},"_links":{"self":[{"href":"https:\/\/www.europesays.com\/dk\/wp-json\/wp\/v2\/posts\/119916","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.europesays.com\/dk\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.europesays.com\/dk\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.europesays.com\/dk\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.europesays.com\/dk\/wp-json\/wp\/v2\/comments?post=119916"}],"version-history":[{"count":2,"href":"https:\/\/www.europesays.com\/dk\/wp-json\/wp\/v2\/posts\/119916\/revisions"}],"predecessor-version":[{"id":120261,"href":"https:\/\/www.europesays.com\/dk\/wp-json\/wp\/v2\/posts\/119916\/revisions\/120261"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.europesays.com\/dk\/wp-json\/wp\/v2\/media\/119917"}],"wp:attachment":[{"href":"https:\/\/www.europesays.com\/dk\/wp-json\/wp\/v2\/media?parent=119916"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.europesays.com\/dk\/wp-json\/wp\/v2\/categories?post=119916"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.europesays.com\/dk\/wp-json\/wp\/v2\/tags?post=119916"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}